Nature Cancer, Published online: 01 September 2026; doi:10.1038/s43018-026-01220-4
Chen et al. have developed SlideChat, a multimodal generative artificial intelligence assistant, which they benchmark on 27 pathology tasks across 33 cancer types. Expert pathologists rated the assistant as clinically relevant and accurate.
Nature Cancer, Published online: 15 May 2026; doi:10.1038/s43018-026-01169-4
Zhao and colleagues show that CD300ld, upregulated in pathologically activated neutrophils, mediates contact-dependent suppression of cytotoxic CD8+ T cells by binding to phosphatidylserine, inhibiting antitumor immune responses.
Cell Death Discovery, Published online: 06 April 2026; doi:10.1038/s41420-026-03002-4
Programmed cell death in cancer: targeting necroptosis to kill tumor cell
Nature, Published online: 01 April 2026; doi:10.1038/s41586-026-10333-w
A dual-action force dynamics strategy using a hard silicon template as a nanoimprinting stamp combined with inverted transfer printing is described for the manufacture of high-performance full-colour ultrahigh-resolution quantum dot light-emitting diodes (LEDs) for active-matrix displays, while revealing electric-field reconstruction in nanoscale arrays and introducing dielectric matching to mitigate field concentration and performance degradation.
Cell Death Discovery, Published online: 31 March 2026; doi:10.1038/s41420-026-03014-0
Doxorubicin promotes the production of inflammatory cytokines in tumor-associated macrophages through activating lactate dehydrogenase A
Nature, Published online: 13 March 2026; doi:10.1038/s41586-026-10376-z
Author Correction: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer
Nature, Published online: 11 March 2026; doi:10.1038/s41586-026-10240-0
Marburgvirus glycoprotein binds to the endosomal receptor NPC1 in a distinct orientation with higher affinity compared with Ebola virus glycoprotein, accompanied by fusion-relevant rearrangements, enabling more efficient viral entry.
Nature, Published online: 11 March 2026; doi:10.1038/s41586-026-10244-w
A clinical trial testing whether monitoring ctDNA clearance during treatment for nasopharyngeal cancer could be used to inform decisions about an individual’s subsequent therapeutic programme shows promising results.
Login